Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03168334 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 801
- Enrollment target
NCT03168334 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 801 participants.
The verdict
NCT03168334, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 801 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
Interventions
- DRUG IDP-123 Lotion
- DRUG IDP-123 Vehicle Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 801 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2018-07-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03168334
The ClinicalTrials.gov registry entry for NCT03168334 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 801 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IDP-123 Lotion is the first listed.
NCT03168334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03168334 about?
NCT03168334 is a clinical study titled "A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)". This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
What is the current status of trial NCT03168334?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 801 participants. The study started on 2017-07-11. Estimated completion is 2018-07-24.
What interventions are being tested in trial NCT03168334?
The interventions under investigation include: IDP-123 Lotion (DRUG), IDP-123 Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT03168334?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.